Document:

EX-10.1

 Exhibit 10.1 
 SECURITIES PURCHASE AGREEMENT 
 THIS SECURITIES PURCHASE AGREEMENT (this
“Agreement”) is made as of August 13, 2013, by and among SafeStitch Medical, Inc., a Delaware corporation (the “Company”), and the investors listed on Schedule I hereto
(“Investors”). 
 1. Purchase and Sale of Stock. Subject to the terms and conditions of this
Agreement, Investors agree to purchase, and the Company agrees to sell and issue to Investors, that number of shares of the Company’s Series B Preferred Stock, par value $0.01 per share (the “Series B Preferred Stock”), set
forth opposite Investors’ respective names on Schedule I hereto, up to an aggregate of 8,750,000 shares of Series B Preferred Stock (collectively, the “Shares”). Each Share shall be composed of ten, one-tenth
fractions of such Share (each, a “Series B Unit”). The Shares, together with the Series B Units and the Company’s common stock, par value $0.001 per share (“Common Stock”), issuable upon conversion of the
Shares and the Series B Units are referred to collectively as the “Offered Securities.” The purchase price for each Series B Unit shall be $0.40 (the “Per Unit Purchase Price,” and the Per Unit Purchase Price
multiplied by the aggregate number of Series B Units underlying the Shares purchased by an Investor, the “Purchase Price”). The Company’s agreement with each Investor is a separate agreement, and the sale and issuance of the
Series B Units to each Investor is a separate sale and issuance.  
 1.1 First Closing. The first closing of the
purchase and sale of Series B Units (the “First Closing Purchased Units”) shall be held at the offices of Wilson Sonsini Goodrich & Rosati, P.C., 650 Page Mill Road, Palo Alto, California (“WSGR”),
immediately following the Effective Time of the Merger (each as defined in the Merger Agreement), or at such other time and place upon which the Company and Investors shall agree (the “First Closing”). 

1.2 Second Closing. If less than all of the Shares are sold and issued at the First Closing, then, subject to the terms and
conditions of this Agreement, the Company may sell and issue at a second closing (the “Second Closing,” the First Closing and the Second Closing shall each be a “Closing”), within 14 days after the First Closing, up
to the balance of the unissued Shares (the “Second Closing Purchased Units”) to such persons or entities as may be approved by the Company in its sole discretion. The sale and issuance in the Second Closing shall be on the same
terms and conditions as those contained herein, and such persons or entities shall, upon execution and delivery of the relevant signature pages, including a counterpart signature page to this Agreement, become parties to, and be bound by, this
Agreement. Subject to applicable Law, promptly following the Second Closing, the Company shall file an amendment to its Amended and Restated Certificate of Incorporation wherein each issued and outstanding Series B Unit shall automatically convert
into one (1) outstanding share of Common Stock. 
 1.3 Delivery. At the applicable Closing, each Investor shall pay
the Purchase Price for the First Closing Purchased Units and Second Closing Purchased Units as set forth opposite such Investor’s name on the Schedule of Investors attached hereto as Schedule I by (a) cashier’s check,
evidencing immediately available funds, payable to the Company, (b) wire transfer of immediately available funds in accordance with the Company’s wire instructions attached hereto as Schedule II, (c) cancellation of
indebtedness held by such Investor, including with respect to the First Closing, 

 
under outstanding convertible promissory notes issued by TransEnterix, Inc. (“TransEnterix”) to such Investor on August 5, 2013, or (d) any combination of the
foregoing. In the event that payment by an Investor is made, in whole or in part, by cancellation of the indebtedness specified by the immediately preceding clause (c), then such Investor shall surrender to the Company for cancellation at the
Closing evidence of such indebtedness or shall execute an instrument of cancellation in form and substance acceptable to the Company. Within five (5) business days following the Closing, the Company shall deliver to the Investors a certificate
representing the Series B Units being purchased thereby (the “Series B Unit Certificates”). 
 2.
Incorporation of Certain Representations and Warranties from Merger Agreement. The representations and warranties made by TransEnterix to the Company as set forth in Article III, Sections 3.01 through 3.19 of that certain Agreement and Plan
of Merger (the “Merger Agreement”) by and among the Company, Tweety Acquisition Corp., a Delaware corporation and a direct wholly owned subsidiary of the Company (“Merger Sub”), and TransEnterix, a Delaware
corporation (“TransEnterix”), and the representations and warranties made by the Company to TransEnterix as set forth in Article IV Sections 4.01 through 4.20 of the Merger Agreement, with such representations and warranties as
qualified by the exceptions disclosed by each of the Company and TransEnterix to other as set forth in their Disclosure Schedules to the Merger Agreement, are incorporated herein by reference and deemed made by the Company to the Investors as of the
First Closing (except to the extent that any such representations and warranties are made as of a specific date, in which case such representations and warranties are made as of such date). 

3. Representations, Warranties and Covenants of the Investors. Each investor hereby represents, warrants, and covenants to the
Company that: 
 3.1 Authorization. Such Investor has full power and authority to execute and deliver, and to consummate
the transactions contemplated by this Agreement. All corporate, limited liability company or other similar action on the part of such Investor, its officers, directors, members, managers and stockholders necessary for (i) the execution and
delivery of, and the consummation of the transactions contemplated by, this Agreement, and (ii) as of the Closing, the performance of all obligations of such Investor under this Agreement, has been taken. This Agreement, upon execution and
delivery by such Investor and assuming the due and proper execution and delivery by the Company, constitutes a legal, valid and binding obligation of such Investor, enforceable in accordance with its terms, except as may be limited by
(i) applicable bankruptcy, insolvency, reorganization or other laws of general application relating to or affecting the enforcement of creditors rights generally, and (ii) the effect of rules of law governing the availability of equitable
remedies. 
 3.2 Purchase Entirely for Own Account. Such Investor represents that the Series B Units will be acquired for
investment by such Investor for such Investor’s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that such Investor has no present intention of selling, granting any
participation in, or otherwise distributing the same. By executing this Agreement, such Investor further represents that Investor does not have any contract, undertaking, agreement or arrangement with any Person to sell, transfer or grant
participations to such Person or to any third Person, with respect to any of the Series B Units. 

  
 -2-

 3.3 Disclosure of Information. Such Investor has received all information it
considers necessary or appropriate for deciding whether to purchase the Offered Securities. Such Investor further represents that it has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of
the offering of the Offered Securities and the business, properties, prospects and financial condition of the Company. Such Investor has received a complete copy of the Merger Agreement, the Registration Rights Agreement (as defined in
Section 4) and the Lockup Agreement (as defined in Section 4) and has reviewed and understands the terms and conditions of such agreements in their entirety. 
 3.4 Investment Experience. Such Investor is an investor in securities of companies in the development stage and acknowledges that it is able to appropriately identify the inherent risks associated
with, and can bear the economic risk of the total loss of its investment in the Offered Securities, and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment in the
Offered Securities. Such Investor has not been organized for the purpose of acquiring the Offered Securities. 
 3.5
Accredited Investor. Such Investor is an “accredited investor” as defined in Rule 501 of Regulation D promulgated under the Securities Act of 1933, as amended (the “Act”). 

3.6 Restricted Securities. Such Investor understands that the Offered Securities are “restricted securities” as defined
in Rule 144 promulgated under the Act inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable regulations such securities may not be resold without registration
under the Act, except in certain limited circumstances. Such Investor is familiar with Rule 144, as presently in effect, and understands the resale limitations imposed thereby and by the Act. 

3.7 Reliance on Exemptions. Such Investor understands that the Offered Securities are being offered and sold in reliance upon
specific exemptions from the registration requirements of the Act and state securities laws and that the Company is relying upon the truth and accuracy of, and such Investor’s compliance with, the representations, warranties, covenants,
agreements, acknowledgments and understandings of such Investor contained in this Agreement in order to determine the availability of such exemptions and the eligibility of Investor to acquire the Offered Securities. 

3.8 Further Limitations on Disposition. Without in any way limiting the representations set forth above, such Investor further
agrees not to make any disposition of all or any portion of the Offered Securities unless and until the transferee thereof has agreed in writing for the benefit of the Company to be bound by this section to the extent this section is applicable,
and: 
 (a) There is then in effect a registration statement under the Act covering such proposed disposition and such
disposition is made in accordance with such registration statement; or 
 (b) If requested by the Company, such Investor shall
have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not require registration of such shares under the Act. 

  
 -3-

 Each Investor agrees that it will promptly notify the Company of any material changes in the
information set forth in any registration statement regarding the Investor or its plan of distribution. 
 3.9 Residency.
Such Investor’s principal executive offices, or primary residence, as applicable, are in the jurisdiction set forth under such Investor’s name on the Schedule of Investors attached hereto. 

3.10 No Brokers. Except for Perella Weinberg Partners, no broker, investment banker, financial advisor or other individual,
corporation, general or limited partnership, limited liability company, firm, joint venture, association, enterprise, joint securities company, trust, unincorporated organization or other person or entity is entitled to any broker’s,
finder’s, financial advisor’s or other similar fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of such Investor or of its affiliates. 

3.11 Additional Trading Limitations. Such Investor has not directly or indirectly, nor has any Person acting
on behalf of or pursuant to any understanding with such Investor, engaged in any transactions in the securities of the Company (including, without limitations, any Short Sales involving the Company’s securities) since the earlier to occur of
(1) the time that such Investor was first contacted by the Company or any other Person regarding an investment in the Company and (2) the 20th day prior to the public announcement of the transactions contemplated by this Agreement. Such Investor covenants that
neither it nor any Person acting on its behalf or pursuant to any understanding with it will engage in any transactions in the securities of the Company (including Short Sales) prior to the time that the transactions contemplated by this Agreement
are publicly disclosed. For purposes of this section, a “Short Sale” includes, without limitation, all “short sales” as defined in Rule 200 promulgated under Regulation SHO under the Exchange Act and all types of direct and
indirect stock pledges, forward sale contracts, options, puts, calls, swaps and similar arrangements (including on a total return basis), and sales and other transactions through non-U.S. broker dealers or foreign regulated brokers. 

3.12 Legends. Such Investor agrees that each Series B Unit Certificate and each certificate evidencing shares of Common Stock
issuable upon conversion of Shares and Series B Units shall bear legends in substantially the following forms: 

(i) “THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES LAWS AND ARE “RESTRICTED SECURITIES” AS DEFINED IN RULE 144 PROMULGATED UNDER THE SECURITIES ACT. THE SECURITIES MAY NOT BE SOLD OR OFFERED FOR SALE OR OTHERWISE DISTRIBUTED
EXCEPT (I) IN CONJUNCTION WITH AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT, (II) IN COMPLIANCE WITH RULE 144, OR (III) PURSUANT TO AN OPINION OF COUNSEL SATISFACTORY TO THE ISSUER OF THESE
SECURITIES THAT SUCH REGISTRATION OR COMPLIANCE IS NOT REQUIRED AS TO SUCH SALE, OFFER OR DISTRIBUTION.” 

(ii) Any other legends required by applicable blue sky or state securities laws. 

  
 -4-

 The Company need not register a transfer of any Series B Units, and may also instruct its transfer agent not
to register a transfer of any Series B Units, unless the conditions specified in the foregoing legends are satisfied to the extent applicable. 
 4. Registration Procedures and Expenses; Lockup. At the applicable Closing, each Investor shall execute and deliver (i) a copy of that certain Registration Rights Agreement, substantially in
the form attached as Exhibit A, by and among the Company and the other parties thereto in respect of the Common Stock issuable upon conversion of the Shares and the Series B Units held by such Investor (the “Registration Rights
Agreement”) and (ii) a Lock-up and Voting Agreement, substantially in the form attached as Exhibit B, in respect of the Offered Securities and any other voting securities of the Company held by such Investor (each, a
“Lockup Agreement”). 
 5. Conditions of Each Investor’s Obligations at First Closing. The
obligations of each Investor participating in the Closing to accept delivery of the First Closing Purchased Units and to pay the Purchase Price therefor are subject to the fulfillment on or before the First Closing of each of the following
conditions, any one or more of which may be waived by an Investor with respect to such Investor’s obligation: 
 5.1
Representations and Warranties. The representations and warranties contained in Section 2 shall be true in all material respects on and as of the First Closing with the same effect as though such representations and warranties had been
made on and as of the date of the First Closing (except to the extent that any such representations and warranties are made as of a specific date, in which case such representations and warranties shall be true on and as of such date). 

5.2 Performance. The Company shall have performed and complied in all material respects with all agreements, obligations and
conditions contained in this Agreement that are required to be performed or complied with by it on or before the First Closing. 

5.3 Consummation of Merger. The Merger (as defined in the Merger Agreement) shall have been consummated. 

6. Conditions of the Company’s Obligations at the First Closing. The obligations of the Company to sell and issue the First
Closing Purchased Units to an Investor participating in the First Closing are subject to the fulfillment on or before the First Closing of each of the following conditions by such Investor, any one or more of which may be waived by the Company:

 6.1 Representations and Warranties. The representations and warranties of the Investor contained in Section 3
shall be true and correct on and as of the First Closing with the same effect as though such representations and warranties had been made on and as of the First Closing. 
 6.2 Minimum Shares. Investors shall have agreed to purchase for no fewer than an aggregate of 7,500,000 Shares under this Agreement. 

  
 -5-

 6.3 Payment of Purchase Price. The receipt of payment of the full Purchase Price in
accordance with Section 1.3. 
 6.4 Consummation of Merger. The Merger (as defined in the Merger Agreement) shall
have been consummated. 
 6.5 Performance. The Investor shall have performed and complied in all material respects with
all agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by it on or before the First Closing, including, but not limited to, execution and delivery by such Investor of the
Registration Rights Agreement and the Lockup Agreement. 
 7. Conditions of Each Investor’s Obligations at the Second
Closing. The obligations of each Investor participating in the Second Closing to accept delivery of the Second Closing Purchased Units and to pay the Purchase Price therefor are subject to the fulfillment on or before the Second Closing of each
of the following conditions, any one or more of which may be waived by an Investor with respect to such Investor’s obligation: 
 7.1 Performance. The Company shall have performed and complied in all material respects with all agreements, obligations and conditions contained in this Agreement that are required to be performed
or complied with by it on or before the Second Closing. 
 8. Conditions of the Company’s Obligations at the Second
Closing. The obligations of the Company to sell and issue the Second Closing Units to any Investor participating in the Second Closing are subject to the fulfillment on or before the Second Closing of each of the following conditions by such
Investor, any one or more of which may be waived by the Company: 
 8.1 Representations and Warranties. The
representations and warranties of the Investor contained in Section 3 shall be true and correct on and as of the Second Closing with the same effect as though such representations and warranties had been made on and as of the Second Closing.

 8.2 Payment of Purchase Price. The receipt of payment of the full Purchase Price in accordance with Section 1.3.

 8.3 Performance. The Investor shall have performed and complied in all material respects with all agreements,
obligations and conditions contained in this Agreement that are required to be performed or complied with by it on or before the Second Closing, including, but not limited to, execution and delivery by such Investor of the Registration Rights
Agreement and the Lockup Agreement. 
 9. Miscellaneous. 

9.1 Survival of Warranties. The warranties, representations and covenants of the Company and Investors contained in or made
pursuant to this Agreement shall survive for one (1) year after the execution and delivery of this Agreement. 

  
 -6-

 9.2 Assignment; Successors and Assigns. No provision of this Agreement may be
assigned by any Investor without the prior written consent of the Company. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assigns any
rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 
 9.3 Governing Law. This Agreement shall be governed by and construed under the laws of the State of Delaware as applied to agreements among Delaware residents entered into and to be performed
entirely within Delaware. 
 9.4 Counterparts; Facsimile Signatures. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Facsimile or other electronically scanned and transmitted signatures, including by email attachment, shall be deemed
originals for all purposes of this Agreement. 
 9.5 Titles and Subtitles. The titles and subtitles used in this
Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 
 9.6
Notices, etc. All notices and other communications required or permitted hereunder shall be in writing and shall be sent by personal delivery, facsimile, overnight courier or mailed by certified or registered mail, postage prepaid, return
receipt requested, to the facsimile number or address as follows: 
 Company: 

SafeStitch Medical, Inc. 
 4400 Biscayne Blvd 
 Miami, FL 33137 

Facsimile: 305-575-4130 
 Attn: Jeffrey Spragens, CEO 
 jgspragens@safestitch.com 

  
 -7-

 with a copy to: 
 SafeStitch Medical, Inc. 
 4400 Biscayne Blvd 

Miami, FL 33137 

Facsimile: 305-575-4130 
 Attn: Joshua Weingard, Chief Legal Officer 
 jweingard@safestitch.com 

with a copy (which shall not constitute notice) to: 
 Wilson Sonsini Goodrich & Rosati, P.C. 
 650 Page Mill Road 

Palo Alto, CA 94304 
 Facsimile: (650) 493-6811 
 Attention: Philip H. Oettinger 

and 
 Greenberg
Traurig, P.A. 
 333 S.E. 2nd Avenue, Suite 4400 
 Miami, FL 33131 
 Facsimile: (305) 961-7756 

Attention: Robert L. Grossman 
 Investors: 
 To the facsimile number or address for each respective Investor set
forth in Schedule I hereto. 
 Agent: 
 Perella Weinberg Partners 
 767 Fifth Avenue 

New York, NY 10153 
 Facsimile: (212) 287-3201 
 Attention: Philippe McAuliffe 

or to such other facsimile number or address provided to the parties to this Agreement in accordance with this Section 9.6. Such notices or other
communications shall be deemed delivered upon receipt, in the case of overnight delivery, personal delivery or facsimile transmission (as evidenced by the confirmation thereof), or three (3) days after deposit in the mails (as determined by
reference to the postmark). 
 9.7 Expenses. Irrespective of whether any Closing is effected, each party shall pay its
own costs and expenses that it incurs with respect to the negotiation, execution, delivery and performance of this Agreement. If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement, the prevailing party
shall be entitled to attorney’s fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. 

  
 -8-

 9.8 Amendments and Waivers. Any term of this Agreement may be amended or modified
only in an instrument in writing executed by the Company and Investors holding a majority of the Series B Units issued and sold as of the time of such amendment or modification. Any amendment effected in accordance with this paragraph shall be
binding upon each holder of any Offered Securities purchased under this Agreement at the time outstanding (including securities into which such securities are convertible), each future holder of all such securities, and the Company. No waiver of any
provision this Agreement shall be binding unless executed in writing by the party to be bound thereby. No waiver of any provision of this Agreement shall be deemed or shall constitute a waiver of any other provision hereof (regardless of whether
similar), nor shall any such waiver constitute a continuing waiver unless otherwise expressly provided. 
 9.9 Independent
Nature of Investors’ Obligations and Rights. The obligations of each Investor under this Agreement are several and not joint with the obligations of any other Investor, and no Investor shall be responsible in any way for the performance of
the obligations of any other Investor under this Agreement. The decision of each Investor to purchase Offered Securities pursuant to this Agreement has been made by such Investor independently of any other Investor. Nothing contained herein, and no
action taken by any Investor pursuant hereto shall be deemed to constitute the Investors as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Investors are in any way acting in concert or a
group with respect to such obligations or the transactions contemplated by this Agreement. Each Investor acknowledges that no other Investor has acted as agent for such Investor in connection with making its investment hereunder and that no Investor
will be acting as agent of such Investor in connection with monitoring its investment in the Offering Securities or enforcing its rights under this Agreement. Each Investor will be entitled to independently protect and enforce its rights, including
without limitation the rights arising out of this Agreement and it shall not be necessary for any other Investor to be joined as an additional party in any proceeding for such purpose. The Company acknowledges that each of the Investors has been
provided with the same Agreement for the purpose of closing a transaction with multiple Investors and not because it was required or requested to do so by any Investor. 
 9.10 Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded from this Agreement and the balance of the
Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms. 

9.11 Entire Agreement. This Agreement and the documents referred to herein constitute the entire agreement among the parties and
no party shall be liable or bound to any other party in any manner by any warranties, representations, or covenants except as specifically set forth herein or therein. 
 [Signature Page Follows] 

  
 -9-

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	COMPANY:
	
	SAFESTITCH MEDICAL, INC.
		
	By:	 	 /s/ Jeffrey G. Spragens

		 	Jeffrey G. Spragens
		 	President and Chief Executive Officer

  
 [Signature
Page to Securities Purchase Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
	INVESTORS:
	
	KWANG SHUN COMPANY LIMITED
		
	By:	 	 /s/ Chang Hsiu-Yen

		 	Name:	 	Chang Hsiu-Yen
		 	Title:	 	Director

 [Signature Page to Securities Purchase Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
	INVESTORS:
	
	CHUNG CHIA COMPANY LIMITED
		
	By:	 	 /s/ Hsu Tsui Hua

		 	Name:	 	Hsu Tsui Hua
		 	Title:	 	Director

 [Signature Page to SafeStitch Medical, Inc. Securities Purchase Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
	INVESTORS:
	
	HSU GAMMA INVESTMENTS, L.P.
		
	By:	 	 /s/ Jane H. Hsiao

		 	Name:	 	Jane H. Hsiao, Ph.D., MBA
		 	Title:	 	General Partner

 [Signature Page to Securities Purchase Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
	INVESTORS:
		
		 	 /s/ Jane H. Hsiao

		 	Name:	 	Jane H. Hsiao, Ph.D., MBA

 [Signature Page to Securities Purchase Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
	INVESTORS:
	
	FROST GAMMA INVESTMENTS TRUST
		
	By:	 	 /s/ Phillip Frost

		 	Name:	 	Phillip Frost
		 	Title:	 	Trustee

 [Signature Page to Securities Purchase Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
	INVESTOR:
	
	SV LIFE SCIENCES FUND IV, L.P.
	BY:	 	SV Life Sciences Fund IV (GP), L.P.,
		 	its sole General Partner
	By:	 	SVLSF IV, LLC, its sole General Partner
		
	By:	 	 /s/ Denise W. Marks

		 	Name:	 	Denise W. Marks
		 	Title:	 	SVLSF IV, LLC, Member
	
	SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L.P.
	BY:	 	SV Life Sciences Fund IV (GP), L.P.,
		 	its sole General Partner
	By:	 	SVLSF IV, LLC, its sole General Partner
		
	By:	 	 /s/ Denise W. Marks

		 	Name:	 	Denise W. Marks
		 	Title:	 	SVLSF IV, LLC, Member

 [Signature Page to Securities Purchase Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
	INVESTOR:
	
	SYNERGY LIFE SCIENCE PARTNERS, L.P.
		
	By:	 	 /s/ Mudit K. Jain

		 	Name:	 	Mudit K. Jain, PhD
		 	Title:	 	Managing Director

 [Signature Page to Securities Purchase Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTOR:
	
	AISLING CAPITAL III, LP
	
	 /s/ Lloyd Appel

	Name:	 	Lloyd Appel
	Title:	 	CFO
	
	Aisling Capital III, L.P.
	888 Seventh Avenue, 30th Floor
	New York, NY 10106
	Attn: Aftab Kherani
	Fax: 212 651 6379
	
	With a required copy to:
	
	McDermott Will & Emery LLP
	340 Madison Avenue
	New York, NY 10173-1922
	Attn: Todd Finger
	Fax: 212 547 5444

 [Signature Page to Securities Purchase Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
	INVESTOR:
	
	INTERSOUTH PARTNERS VII, L.P.
	BY:	 	Intersouth Associates VII, LLC
		 	its General Partner
		
	By:	 	 /s/ Dennis Dougherty

		 	Name:	 	Dennis Dougherty
		 	Title:	 	Managing Member

 [Signature Page to Securities Purchase Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTOR:
	
	INTERNATIONAL BIOTECHNOLOGY TRUST PLC
		
	By:	 	 /s/ Nick Coleman

	Name:	 	Nick Coleman
	Title:	 	IBT Authorised Signatory
	
	Address for Notice:
	55 Moorgate
	London, EC2R 6PA
	United Kingdom

 [Signature Page to Securities Purchase Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTOR:
	
	QUAKER BIOVENTURES II, L.P.
	BY:	 	Quaker BioVentures Capital II, L.P., its General Partner
	By:	 	Quaker BioVentures Capital II, LLC, its General Partner
		
	By:	 	 /s/ Matthew B. Rieke

		 	Matthew B. Rieke, Vice President

 [Signature Page to Securities Purchase Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
	INVESTOR:
	
	KFBSF PRIVATE EQUITY FUND I, L.P.
		
	By:	 	 /s/ David Stevens 8/13/13

		 	Name:	 	David Stevens
		 	Title:	 	Manager

 [Signature Page to Securities Purchase Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
	INVESTOR:
	
	STEPSTONE-SYN INVESTMENTS, L.L.L.P.
	BY:	 	StepStone PC GP, LLC
		
	By:	 	 /s/ Jason Ment

		 	Name:	 	Jason Ment
		 	Title:	 	Partner & General Counsel

 [Signature Page to Securities Purchase Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
	INVESTOR:
		
	By:	 	 /s/ Donald L. Laurie

		 	Name:	 	Donald L. Laurie
		 	Title:	 	

 [Signature Page to Securities Purchase Agreement]EX-10.2

 Exhibit 10.2 
 LOCK-UP AND VOTING AGREEMENT 
 THIS LOCK-UP AND VOTING AGREEMENT, as may be
amended, supplemented or modified from time to time in accordance with the terms hereof, is made as of August     , 2013 (this “Agreement”) by and among SafeStitch Medical, Inc., a Delaware corporation (the
“Company”) and the undersigned investor (the “Investor”). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below).

 WHEREAS, the Company, Tweety Acquisition Corp., a Delaware corporation and a direct wholly-owned subsidiary of the Company
(“Merger Sub”), and TransEnterix, Inc., a Delaware corporation (“TransEnterix”), are entering into or have entered into an Agreement and Plan of Merger (the “Merger Agreement”) pursuant to which
Merger Sub shall be merged with and into TransEnterix in accordance with the Delaware General Corporation Law and TransEnterix shall be the surviving corporation (the “Merger”); 

WHEREAS, certain existing stockholders of the Company and TransEnterix intend to subscribe, pursuant to Securities Purchase Agreements
(the “Securities Purchase Agreements”), for shares of capital stock of the Company (“Company Capital Stock”), with the consummation of such subscription to occur immediately after the closing of the Merger (the
“Equity Financing,” and, together with the Merger, the “Transactions”); 
 WHEREAS,
(i) pursuant to the Merger, certain investors of TransEnterix shall receive shares of Company Capital Stock in exchange for the shares of stock of TransEnterix formerly held by them, on the terms as set forth in the Merger Agreement, and
(ii) pursuant to the Equity Financing, certain investors of TransEnterix and Sesame shall receive shares of Company Capital Stock in exchange for cash or other consideration, on the terms as set forth in the Securities Purchase Agreements;

 WHEREAS, as a condition and inducement to TransEnterix and the Company entering into the Merger Agreement and the Securities
Purchase Agreements, as applicable, and incurring the obligations set forth therein, the Investor agrees to be bound by the covenants contained in this Agreement; 
 NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein and for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties
hereto agree as follows: 
 1. Definitions and Interpretation. 

(a) Certain Definitions. As used in this Agreement, and unless the context requires a different meaning, the following terms have
the meanings indicated: 
 “Agreement” has the meaning set forth in the Preamble. 

“Affiliate” means any Person who is an “affiliate” as defined in Rule 12b-2 promulgated under the Exchange
Act. 

 “Board of Directors” means the Board of Directors of the Company.

 “Business Day” means a day other than a Saturday, Sunday or other day on which banks located in New York,
New York are authorized or required by law to close. 
 “Code” means the Internal Revenue Code of 1986, as
amended. 
 “Consummation Date” shall mean the first date on which the closing of the Merger and the initial
closing of the Equity Financing shall have both occurred. 
 “Covered Securities” shall mean, with respect to
any Holder, any of the following: (i) any and all shares of Company Capital Stock which are owned by such Holder as of the Consummation Date, (ii) any shares of Company Capital Stock issuable upon exercise, conversion or exchange of any
securities of the Company which are owned by such Holder as of the Consummation Date, (iii) any securities of the Company issued in respect of the shares of Company Capital Stock issued or issuable to any of the Holders by way of stock dividend
or stock split or in connection with a combination of shares, recapitalization, merger, consolidation or other reorganization or otherwise and any shares of Company Capital Stock issuable upon conversion, exercise or exchange thereof, in each case
to the extent relating to any securities of the Company which were owned by such Holder as of the Consummation Date and (iv) any other securities of the Company issued or issuable to any Holder that are convertible into or exercisable or
exchangeable for Company Capital Stock, whether at the option of the Holder or otherwise, in each case to the extent relating to any securities of the Company which were owned by such Holder as of the Consummation Date; provided, in all
cases, that for any Investor who receives any such securities in a subsequent closing of the Equity Financing occurring after the Consummation Date, such securities shall also be deemed to be Covered Securities and shall be deemed to have been held
by such Investor as of the Consummation Date for purposes of Section 2; provided, further, that for the avoidance of doubt Covered Securities shall not include Company Capital Stock acquired by any Holder in the open market on or
after the Consummation Date. 
 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the
rules and regulations thereunder. 
 “Holder” means the Investor and any Permitted Transferee thereof to whom
Covered Securities are transferred in accordance with Section 2. 
 “Investor” has the meaning set forth
in the Preamble. 
 “Lock-up Period,” means each of (i) the period commencing on the Consummation Date to
and including the date that is twelve (12) months following the Consummation Date (the “First Lock-up Period”); (ii) the period commencing on the Consummation Date to and including the date that is eighteen
(18) months following the Consummation Date (the “Second Lock-up Period”); and (iii) the period commencing on the Consummation Date to and including the date that is twenty-four (24) months following the Consummation
Date (the “Third Lock-up Period”). 
 “Merger” has the meaning set forth in the Recitals.

  
 - 2 -

 “Merger Agreement” has the meaning set forth in the Recitals. 

“Merger Sub” has the meaning set forth in the Recitals. 

“Permitted Transfer” has the meaning set forth in Section 2. 

“Permitted Transferee” means, (i) with respect to any Holder who is an individual, (x) a member of such
Holder’s immediate family (which shall mean any relationship by blood, marriage or adoption, not more remote than first cousin) or a trust, corporation, partnership or limited liability company for the benefit of an immediate family member, all
of the beneficial interests of which shall be held by such Holder or one or more members of such Holder’s immediate family, and (y) such Holder’s heirs, successors, administrators and executor and any beneficiary pursuant to will,
other testamentary document or applicable laws of descent, (ii) with respect to any Holder that is an entity, any Affiliate of such entity (including any investment fund or other entity controlled or managed by such Holder) and such
Holder’s partners, limited partners, members, stockholders and other equity holders, (iii) with respect to any Holder that is a trust, to a trustee or beneficiary of the trust and (iv) a recipient of a bona fide gift or gifts of
Covered Securities. 
 “Person” means any individual, firm, corporation, partnership, limited liability
company, trust, incorporated or unincorporated association, joint venture, joint stock company, government (or an agency or political subdivision thereof) or other entity of any kind, and shall include any successor (by merger or otherwise) of such
entity. 
 “SEC” means the Securities Exchange Commission, or any successor entity thereto. 

“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations thereunder. 

“Transfer” means, with respect to any security, the offer for sale, sale, pledge, sale of any option or contract to
purchase, purchase of any option or contract to sell, grant of any option, right or warrant to purchase, share lending arrangement or other transfer or disposition or encumbrance (or any transaction or device that is designed to or could be expected
to result in the transfer or the disposition by any Person at any time in the future), whether directly or indirectly, of such security, and shall include the entering into of any swap, hedge or other derivatives transaction or other transaction
that transfers to another, in whole or in part, any rights, economic benefits or consequences, or risks of ownership, including by way of settlement by delivery of such security or other securities in cash or otherwise. 

“TransEnterix” has the meaning set forth in the Recitals. 

(b) Interpretation. Unless otherwise noted: 

(i) All references to laws, rules, regulations and forms in this Agreement shall be deemed to be references to such laws,
rules, regulations and forms, as amended from time to time or, to the extent replaced, the comparable successor thereto in effect at the time. 

  
 - 3 -

 (ii) All references to agencies, self-regulatory organizations or
governmental entities in this Agreement shall be deemed to be references to the comparable successor thereto. 

(iii) All references to agreements and other contractual instruments shall be deemed to be references to such agreements
or other instruments as they may be amended from time to time. 
 Whenever the words “include,” “includes,”
or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation.” 
 2. Transfers. During the applicable Lock-up Period, Transfers of Covered Securities shall not be permitted except in accordance with this Section 2 and as set forth in Section 3:

 (a) Each Holder agrees not to Transfer any portion of its Covered Securities during the First Lock-up Period. 

(b) Each Holder agrees that it may Transfer (i) no more than fifty percent (50%) in the aggregate of all the Covered Securities
held by such Holder as of the Consummation Date, from the period beginning on the first calendar day following the end of the First Lock-up Period until the last calendar day of the Second Lock-up Period; and (ii) no more than seventy-five
percent (75%) in the aggregate of all the Covered Securities held by such Holder as of the Consummation Date (including with any Covered Securities transferred in any prior Lock-up Period), from the period beginning on the first calendar day
following the end of the Second Lock-up Period until the last calendar day of the Third Lock-up Period. The transfer restrictions set forth in this Agreement shall cease to apply commencing on the first calendar day immediately following the last
day of the Third Lock-up Period. 
 (c) With respect to any Holder, the limitation on Transfers contained in Sections 2(a) and
2(b) shall not apply to (i) Transfers to Permitted Transferees of such Holder, (ii) Transfers to the Company, and (iii) Transfers by a Holder and its Affiliates to any other Holder and its Affiliates; provided, however,
that any such transferee that is not a Holder shall execute and deliver to the Company a joinder agreement in form and substance attached as Exhibit A hereto, to evidence its agreement to be bound by, and to comply with, this Agreement as a
Holder (each such Transfer described in clauses (i)-(iii) of this Section 2(b), subject to compliance with Section 3, a “Permitted Transfer”). 
 (d) The foregoing restrictions of this Section 2 shall not limit the right of any Holder during any Lock-Up Period to make any demand for or exercise any right with respect to, the registration of
any Covered Securities or any securities convertible into or exercisable or exchangeable for Covered Securities so long as there are no sales of such shares of Covered Securities during any Lock-Up Period. In addition, no provision herein shall be
deemed to restrict or prohibit the exercise or exchange by any Holder of any option or warrant to acquire shares of Covered Securities, or any other security exchangeable or exercisable for, or convertible into, Covered Securities; provided
that such Holder does not transfer the Covered Securities acquired on such exercise or exchange during any Lock-Up Period, unless otherwise permitted pursuant to the terms of this Agreement. 

  
 - 4 -

 (e) Notwithstanding any other provisions of this Section 2, any Holder shall be
permitted to make transfers, sales, tenders or other dispositions of Covered Securities pursuant to a tender offer for securities of the Company or any other transaction, including, without limitation, a merger, consolidation or other business
combination, involving a change of control of the Company (including, without limitation, entering into any lock-up, voting or similar agreement pursuant to which such Holder may agree to transfer, sell, tender or otherwise dispose of Covered
Securities in connection with any such transaction, or vote any Covered Securities in favor of any such transaction in accordance with Article 5 or otherwise), provided that all Covered Securities subject to this agreement that are not so
transferred, sold, tendered or otherwise disposed of remain subject to this Agreement; and provided further that it shall be a condition of transfer, sale, tender or other disposition that if such tender offer or other transaction is not completed,
any Covered Securities subject to this Agreement shall remain subject to the restrictions herein. 
 3. Permitted Transfers;
No Effect of Transfers. 
 (a) No Transfer shall be deemed a Permitted Transfer hereunder unless and until at the time of
such Transfer, as contemplated by Section 2 hereof, such Permitted Transferee (i) is at such time a Holder or (ii) executes and delivers to the Company a joinder agreement in form and substance attached as Exhibit A hereto, to
evidence its agreement to be bound by, and to comply with, this Agreement as a Holder. 
 (b) No Transfer of any Covered
Securities in violation of any provision of this Agreement will be effective to pass any title to, or create any interest in favor of, any Person. Any Holder who intentionally and knowingly attempts to so effect a Transfer in violation of this
Agreement will be deemed to have committed a material breach of its obligations to the other Holders and to the Company hereunder. 
 4. Restrictive Legend; Stop Transfer Instruction. 
 (a) Certificates
representing the Covered Securities issued on or after the Consummation Date must bear the following legend: 
 “THE SECURITIES REPRESENTED
BY THIS CERTIFICATE ARE SUBJECT TO A LOCK-UP AND VOTING AGREEMENT AMONG THE OWNER OF SUCH SECURITIES OF SAFESTITCH, INC. AND CERTAIN OTHER PARTIES THERETO THAT MATERIALLY RESTRICTS THE TRANSFERABILITY OF THE SECURITIES. BY ACCEPTING ANY INTEREST IN
SUCH SHARES THE PERSON ACCEPTING SUCH INTEREST SHALL BE DEEMED TO AGREE TO AND SHALL BECOME BOUND BY ALL THE PROVISIONS OF SAID AGREEMENT. A COPY OF THE AGREEMENT IS ON FILE WITH THE SECRETARY OF SAFESTITCH, INC..” 

(b) In order to ensure compliance with the provisions contained herein, each Holder agrees that the Company may issue appropriate
“stop transfer” certificates or instructions with the Company’s transfer agent and registrar against the transfer of a Holder’s Covered Securities (irrespective of the date of issuance of such Covered Securities), or otherwise
make adequate provision to restrict the transferability of the Covered Securities, in the event of a transfer other than in compliance with the provisions of this Agreement and that it may make appropriate notations to the same effect in its
records. 

  
 - 5 -

 5. Voting Agreement. During the term of the First Lock-up Period each of the Holders
agrees to vote at any regular or special meeting of stockholders (or by written consent) all Covered Securities held by such Holder in such manner as may be necessary to approve the following actions, if such actions are submitted for a stockholder
vote by the Board of Directors of the Company: 
 (a) amending the Company’s Amended and Restated Certificate of
Incorporation to change the legal name of the Company to “TransEnterix, Inc.”; 
 (b) effecting a reverse stock split
of the outstanding Sesame Common Stock, on the terms approved by the Board of Directors of the Company; and 
 (c) amending the
Company’s 2007 Incentive Compensation Plan (the “Stock Plan”) in order to increase the number of shares of Sesame Common Stock available for issuance under the Stock Plan, provided that no such amendment shall increase
the number of shares available for issuance in excess of 8% of the fully diluted capitalization of the Company (after giving effect to such increase). 
 The voting of shares of Covered Securities may be effected in person, by proxy, by written consent or in any other manner permitted by applicable law. 

6. To secure each Holder’s obligations to vote his, her or its shares of Covered Securities in accordance with this Agreement,
(a) each Holder hereby appoints the Chairman of the Board of Directors and the Chief Executive Officer of the Company, or either of them from time to time, or their respective designees, as such Holder’s true and lawful proxy and attorney,
with the power to act alone and with full power of substitution, to vote all of such Holder’s Covered Securities in favor of the matters set forth in Section 5 and to execute all appropriate instruments consistent with this Agreement on
behalf of such Holder if, and only if, such Holder fails to vote all of such Holder’s Covered Securities or execute such other instruments in accordance with the provisions of Section 5 within five (5) days of the Company’s
written request for such Holder’s written consent or signature. The proxy and power granted by each Holder pursuant to this Section are coupled with an interest and are given to secure the performance of such Holder’s obligations under
Section 5. Each such proxy and power will be irrevocable during the term of the First Lock-up Period. The proxy and power, so long as any Holder is an individual, will survive the death, incompetency and disability of such Holder and, so long
as any Holder is an entity, will survive the merger or reorganization of such Holder. 
 7. Successors and Assigns; Third
Party Beneficiaries. The undersigned understands that the Company and the other parties hereto are relying upon this Agreement in proceeding toward consummation of the Transactions. The undersigned further understands that this Agreement is
irrevocable and shall inure to the benefit of and be binding upon the successors and permitted assigns of the parties hereto as provided herein. No Person other than the parties hereto and their successors and permitted assigns is intended to be a
beneficiary of this Agreement. This Agreement shall not be assigned by the Company except as provided herein. 

  
 - 6 -

 
The Company shall cause any successor or assign (whether by merger, consolidation, sale of assets, recapitalization, reorganization or otherwise) to assume this Agreement as a condition to any
such transaction. 
 8. Termination. This Agreement shall automatically terminate and be of no further force or effect
upon the earlier to occur of (i) the termination of the Merger Agreement, (ii) the first Business Day following the expiration of the Third Lock-up Period and (iii) a Change of Control of the Company; except that
Section 3(b) and Sections 8 through 22 of this Agreement shall survive termination under this Section 8. For purposes of this Section 8, “Change of Control” shall mean either (i) the acquisition of the Company by
another person or entity by means of any transaction or series of related transactions to which the Company is a party (including, without limitation, any stock acquisition, reorganization, merger or consolidation, but excluding any such transaction
if the primary purpose of such transaction is to change the Company’s domicile, and excluding any equity financing the primary purpose of which is to raise operating capital for the Company) that results in a transfer of at least 50% of the
total voting power represented by the Company’s voting securities before such acquisition; or (ii) a sale, lease, or other conveyance of all or substantially all of the Company’s assets. 

9. Remedies. The Holders and the Company, in addition to being entitled to exercise all rights granted by law, shall be entitled
to specific performance of their rights under this Agreement. The Company and the Holders agree that monetary damages would not be adequate compensation for any loss incurred by reason of breach of the provisions of this Agreement and hereby agree
to waive in any action for specific performance the defense that a remedy at law would be adequate or that there is need for a bond. 
 10. Notices. All notices, demands and other communications provide for or permitted hereunder shall be made in writing and shall be made by registered or certified first-class mail, return receipt
requested, telecopy, electronic transmission, courier service or personal delivery: 
  

	 	(i)	If to the Company: 

 SafeStitch
Medical, Inc. 
 635 Davis Drive 
 Suite 300 
 Durham, NC 27713 

Telecopy No.: 919-765-8459 
 Attention: Todd Pope 
 Email: tpope@transenterix.com 

With a copy to: 

Wilson Sonsini Goodrich & Rosati, P.C. 
 650 Page Mill Road 
 Palo Alto, California 94304 

Telecopy: (650) 493-6811 

  
 - 7 -

			
	Attention:	  	Philip H. Oettinger
		  	Robert T. Ishii
	Email:	  	poettinger@wsgr.com
		  	rishii@wsgr.com

  

	 	(ii)	If to the Investor, at the address set forth on the signature page hereto; 

 

	 	(iii)	If to any Holder, as set forth in the applicable joinder agreement. 

 All such notices, demands and other communications shall be deemed to have been duly given when delivered by hand, if personally delivered; when delivered by courier, if delivered by commercial courier
service; five Business Days after being deposited in the mail, postage prepaid, if mailed; and when receipt is acknowledged, if telecopied or electronically transmitted. Any party to be given notice in accordance with this section may designate
another address or Peron for receipt of notices hereunder. 
 11. Headings. The headings in this Agreement are for
convenience of reference only and shall not limit or otherwise affect the meaning hereof. 
 12. Governing Law; Consent to
Jurisdiction. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflict of laws. Each of the parties
(i) irrevocably submits itself to the personal jurisdiction of each state or federal court sitting in the State of Delaware, as well as to the jurisdiction of all courts to which an appeal may be taken from such courts, in any suit, action or
proceeding arising out of or relating to this Agreement or any of the transactions contemplated herein, (ii) agrees that every such suit, action or proceeding shall be brought, heard and determined exclusively in the Court of Chancery of the
State of Delaware (provided that, in the event subject matter jurisdiction is unavailable in or declined by the Court of Chancery, then all such claims shall be brought, heard and determined exclusively in any other state or federal court sitting in
the State of Delaware), (iii) agrees that it shall not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from such court, (iv) agrees not to bring any suit, action or proceeding arising out of or
relating to this Agreement or any of the transactions contemplated herein in any other court, and (v) waives any defense of inconvenient forum to the maintenance of any suit, action or proceeding so brought. 

13. WAIVER OF JURY TRIAL. EACH PARTY TO THIS AGREEMENT KNOWINGLY AND VOLUNTARILY WAIVES, TO THE FULLEST EXTENT PERMITTED BY
APPLICABLE LEGAL REQUIREMENTS, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY ACTION, SUIT OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT. 
 14. Severability. If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule of law or public policy, all other conditions and provisions of
this Agreement shall nevertheless remain in full force and effect. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Agreement
so as to effect the original intent of the parties as closely as possible to the fullest extent permitted by applicable law in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the extent possible.

  
 - 8 -

 15. Rules of Construction. Unless the context otherwise requires, references to
sections or subsections refer to sections or subsections of this Agreement. Terms defined in the singular have a comparable meaning when used in the plural, and vice versa. 
 16. Interpretation. The parties hereto acknowledge and agree that (i) each party hereto and its counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed
to its revision, (ii) the rule of construction to the effect that any ambiguities are resolved against the drafting party shall not be employed in the interpretation of this Agreement and (iii) the terms and provisions of this Agreement
shall be construed fairly as to all parties hereto, regardless of which party was generally responsible for the preparation of this Agreement. 
 17. Entire Agreement. This Agreement is intended by the parties as a final expression of their agreement and intended to be a complete and exclusive statement of the agreement and understanding of
the parties hereto with respect to the subject matter contained herein. There are no restrictions, promises, representations, warranties or undertakings with respect to the subject matter contained herein, other than those set forth or referred to
herein. This Agreement supersedes all prior agreements and understandings among the parties with respect to such subject matter. 
 18. Further Assurances. Each of the parties shall execute such documents and perform such further acts as may be reasonably required or desirable to carry out or to perform the provisions of this
Agreement. 
 19. Other Agreements. Nothing contained in this Agreement shall be deemed to be a waiver of, or release
from, any obligations any party hereto may have under, or any restrictions on the transfer of securities of the Company imposed by any other agreement. 
 20. Counterparts; Facsimile Signatures. This Agreement may be executed in any number of counterparts and by the parties hereto in separate counterparts, each of which when so executed shall be
deemed to be an original and all of which taken together shall constitute one and the same agreement. Facsimile or other electronically scanned and transmitted signatures, including by email attachment, shall be deemed originals for all purposes of
this Agreement. 
 21. Not a Voting Trust. This Agreement is not a voting trust governed by Section 218 of
the Delaware General Corporation Law and should not be interpreted as such. 
 22. Amendments and Waivers. The terms of
this Agreement may be amended and the observance of any term hereof may only be waived only by unanimous written consent of the Company and the Holders. 
 23. Stock Splits, Stock Dividends & Other Issuances. In the event of any issuance of Company Capital Stock hereafter to any of the parties hereto (including, without limitation, in
connection with any stock split, stock dividend, recapitalization, reorganization or the like) such shares shall become subject to this Agreement and shall be endorsed with the legend set forth in Section 4 of this Agreement. 

[Remainder of page intentionally left blank.] 

  
 - 9 -

 IN WITNESS WHEREOF, the undersigned have executed, or have caused to be executed, this
Agreement on the date first written above. 
  

			
	SAFESTITCH MEDICAL, INC.
		
	By:	 	  

	Name:	 	
	Title:	 	

  

			
	[INVESTOR]
		
	Address:	 	  

		 	  

		 	  

	Fax:	 	  

	Email:	 	  

  

Signature Page to Lock-Up Agreement 

 Exhibit A 

Form of Joinder Agreement 
 ACKNOWLEDGMENT AND AGREEMENT 
 Joinder to Lock-Up and Voting
Agreement 
 Relating to SafeStitch, Inc. Capital Stock 

WHEREAS, the undersigned (the “Transferee”) wishes to receive, from
                     (the “Transferor”),
                 shares, par value $0.001 per share, of capital stock (the “Capital Stock”), of SafeStitch, Inc., a Delaware corporation (the
“Company”); 
 WHEREAS, the Capital Stock is subject to that certain Lock-Up and Voting Agreement, dated as of
[DATE], 2013 and as further amended from time to time (the “Agreement”), by and among the Company and that certain investor named therein. Capitalized terms used herein and not otherwise defined are given the meaning assigned
to such terms in the Agreement; 
 WHEREAS, the Transferee has been given a copy of the Agreement and afforded ample opportunity
to read it, and the Transferee is thoroughly familiar with its terms; and 
 WHEREAS, pursuant to the terms of the Agreement,
the Transferor may not Transfer all or any portion of the Transferor’s Capital Stock unless in compliance with the Agreement and in accordance with Section 2 and Section 3 thereof. This Acknowledgment and Agreement constitutes a
joinder agreement as contemplated by Section 3(a) of the Agreement. 
 NOW, THEREFORE, in consideration of the mutual
premises contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and to induce the Transferor to transfer such Capital Stock to the Transferee and the Company to permit such
transfer, the Transferee does hereby acknowledge and agree that (i) the Transferee has been given a copy of the Agreement and ample opportunity to read it, and is thoroughly familiar with its terms, (ii) the Capital Stock are subject to
the terms and conditions set forth in the Agreement and (iii) the Transferee shall become a party to the Agreement and shall be fully bound by, and subject to, all of the covenants, terms and conditions of the Agreement as though an original
party thereto. 
 Signed this      day of             ,
20    , 
  

			
	  

	Transferee:
		
	By:	 	  

	Name:	 	
	Title:	 	

  

Signature Page to Lock-Up Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}]]